Navigation Links
WuXi PharmaTech Announces Licensing Agreement for Patient-Derived Xenograft Models with Mayo Clinic's Center for Individualized Medicine

SHANGHAI, Nov. 4, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, today announced a licensing agreement with Mayo Clinic's Center for Individualized Medicine to expand WuXi's collection of patient-derived xenograft (PDX) mouse models.  These models will support the cancer drug discovery and personalized medicine efforts of WuXi's global customers.

Under this agreement, WuXi has been granted an exclusive license for a panel of patient-derived xenograft models for prevailing cancers in Western countries that have been developed in connection with the center's research and patient care.  The Mayo collection supplements WuXi's unique and extensive Chinese PDX collection, which includes more than 500 Chinese patient-derived xenograft models, more than 220 of which have been deep-sequenced using whole exome sequencing at 100X.  By combining PDX models derived from cancer tissues of patients representing Chinese and Western ancestries, WuXi is creating a single platform to allow its global customers to select highly relevant models with a higher probability of success for testing targeted therapies.

"This agreement with the internationally renowned Mayo Clinic enables WuXi to provide the global research community with a unique single resource that will help advance cancer research through a more relevant and clinically directed approach," said Dr. Ge Li, Chairman and CEO of WuXi.  "We look forward to working with world-class organizations like Mayo Clinic to further strengthen our integrated, open-access R&D services platform, which enables anyone and any company to discover and develop new medicines for improved patient care."

"We are delighted to work with WuXi, an organization with a strong reputation and industry leadership, to make our PDX models broadly available to the global cancer research community," said Dr. Gianrico Farrugia, Director of Mayo Clinic's Center for Individualized Medicine. "We hope use of these models leads to more predictive approaches to the discovery and development of personalized cancer therapies for patients."

Mayo Clinic has a financial interest in the technology mentioned in this news release.  Revenue Mayo receives is used to support the clinic's not-for-profit mission in patient care, education and research.

About WuXi PharmaTech

As a research-driven and customer-focused company, WuXi PharmaTech (Cayman) Inc. provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech.  For more information, please visit:

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech

Aaron Shi
Associate Director of Corporate Communications
WuXi PharmaTech

SOURCE WuXi PharmaTech
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. featured expert Kevin Matras highlights: Core Laboratories NV, Invesco Ltd., Medtronic, Inc., Willbros Group Inc. and WuXi PharmaTech Inc.
2. WuXi PharmaTech Schedules First-Quarter 2013 Earnings Release
3. Breckenridge announces agreement with Aptalis Pharmatech to market Propranolol Hydrochloride Extended-Release Capsules
4. WuXi PharmaTech Receives Letter from AAALAC Commending Animal Care at Suzhou Toxicology Facility as "Exemplary"
5. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2012 Results, Share Repurchase Program
6. WuXi PharmaTech and Open Monoclonal Technology Expand Human Antibody Development and Commercial Opportunities for Asian Regional and Global Pharmaceutical Companies
7. WuXi PharmaTech Schedules Fourth-Quarter 2012 Earnings Release
8. WuXi PharmaTech Presents the 2012 Life Science and Chemistry Awards
9. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2012 Annual General Meeting
10. WuXi PharmaTech Celebrates Dr. Joseph Vaccas Induction into American Chemical Societys Medicinal Chemistry Hall of Fame
11. WuXi PharmaTech and Open Monoclonal Technology Announce OmniRat(TM) Antibody Collaboration
Post Your Comments:
(Date:12/1/2015)... SAN FRANCISCO , Dec. 1, 2015  InCarda ... the development and commercialization of therapies for cardiovascular conditions ... established a subsidiary business in Australia ... clinical trial in Australia in ... with leading investigators and medical centers in ...
(Date:12/1/2015)... and TELTOW, Germany , December ... (SMI) , a leading global manufacturer of eye and ... has included SMI remote eye trackers as a ... healthcare providers assess concussions, eye sight, and medical and ... -oem technology is part of SMI,s mass-market-ready eye tracking ...
(Date:12/1/2015)... -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced ... 2016 as the ex-distribution date for Ampio,s previously announced ... Stock of Aytu BioScience, Inc. As announced, Ampio will ... every five (5) shares of Ampio Common Stock owned ... date will be January 4, 2016. ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic ... addition to the devices for sale in the United States. Clarity is a ... 1064 nm Nd:YAG lasers, into a single platform that is easy to own and ...
(Date:12/1/2015)... ... ... With FCPX Overlay: Grit , users can apply a grit effect ... truly endless, all with a click of a mouse. Each user has full control ... of field and more, all within Final Cut Pro X. , With FCPX Overlay: ...
(Date:11/30/2015)... India (PRWEB) , ... November 30, 2015 , ... ... dental search engine optimization companies, announced today that it has officially launched a ... Third Molar SEO, explained that his company’s new website clearly outlines the benefits ...
(Date:11/30/2015)... ... 2015 , ... The National Association of Professional Women (NAPW) honors ... Year Circle. She is recognized with this prestigious distinction for leadership in estate sales ... more than 850,000 members and over 200 operating Local Chapters. , “I’m pleased to ...
(Date:11/30/2015)... ... November 30, 2015 , ... Until now, the St. ... in the MOMS (Management of Myelomeningocele Study) trial. One of these exclusion criteria was ... a BMI of 18.5 to 24.9 is considered normal, 25 - 29.9 is overweight ...
Breaking Medicine News(10 mins):